UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 21, 2005
ENDOCARE, INC.
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| Delaware |
|
0-27212 |
|
33-0618093 |
(State or Other Jurisdiction of
Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number) |
201 Technology Drive
Irvine, California 92618
(Address of Principal Executive Offices, including zip code)
(949) 450-5400
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
TABLE OF CONTENTS
Item 2.02 Results of Operations and Financial Condition.
On October 25, 2005, members of our management intend to make a presentation at the Emerging Growth
Life Sciences Conference sponsored by C.E. Unterberg, Towbin, using slides containing the
information attached to this Current Report on Form 8-K as Exhibit 99.1.
One of the slides indicates that we expect that our cash used in operations during the quarter
ended September 30, 2005 will be less than $2 million.
This Form 8-K, the information contained herein, and the attached exhibit are furnished to, but not
filed with, the Securities and Exchange Commission. The information contained herein and in the
accompanying exhibit shall not be incorporated by reference to any of our filings with the
Securities and Exchange Commission, whether made before or after the date hereof, regardless of any
general incorporation language in such filing, unless expressly incorporated by specific reference
in such filing.
Item 9.01 Financial Statements and Exhibits.
The exhibit listed below is being furnished with this Form 8-K.
| |
99.1 |
|
Slides to be used in October 25, 2005 presentation. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
|
|
|
|
| |
|
ENDOCARE, INC. |
|
|
|
|
|
|
|
|
|
October 21, 2005
|
|
By:
|
|
/s/ Michael R. Rodriguez |
|
|
|
|
|
|
|
|
|
|
|
|
|
Michael R. Rodriguez |
|
|
|
|
|
|
Senior Vice President, Finance |
|
|
|
|
|
|
and Chief Financial Officer |
|
|